American Century Companies Inc. Buys 23,943 Shares of Regeneron Pharmaceuticals, Inc. $REGN

American Century Companies Inc. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 660,595 shares of the biopharmaceutical company’s stock after acquiring an additional 23,943 shares during the period. American Century Companies Inc.’s holdings in Regeneron Pharmaceuticals were worth $371,436,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Dodge & Cox lifted its holdings in Regeneron Pharmaceuticals by 64.6% in the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after purchasing an additional 1,502,198 shares during the last quarter. Norges Bank acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $628,151,000. Acadian Asset Management LLC grew its holdings in Regeneron Pharmaceuticals by 234.7% during the second quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after purchasing an additional 326,583 shares during the last quarter. Loomis Sayles & Co. L P raised its position in shares of Regeneron Pharmaceuticals by 18.6% in the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after purchasing an additional 305,089 shares during the period. Finally, Invesco Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 26.5% in the second quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock worth $564,808,000 after buying an additional 225,078 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $781.67 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a 50 day moving average of $771.59 and a 200-day moving average of $680.78. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The firm has a market cap of $82.64 billion, a price-to-earnings ratio of 18.81, a PEG ratio of 2.07 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the company earned $12.07 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.05%.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA expanded Dupixent’s U.S. label to include allergic fungal rhinosinusitis in patients aged 6 and up, broadening the drug’s addressable market and adding near‑term upside to revenue forecasts. Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds
• Positive Sentiment: The European Medicines Agency (CHMP) recommended Dupixent for approval to treat chronic spontaneous urticaria (CSU) in children aged 2–11 — if approved this would be the first targeted EU therapy for that pediatric indication, supporting incremental EU sales alongside Sanofi. Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children
• Positive Sentiment: Dupixent remains the growth engine — recent coverage highlights strong sales growth (Dupixent +22.8% y/y in Q4) and continued investor confidence that the franchise can drive Regeneron’s top‑line and multiple expansion. Why Dupixent Keeps Regeneron A Top Big Pharma Pick
• Positive Sentiment: Hedge funds and institutional investors are highlighting Regeneron as a top gene‑therapy/biotech holding, boosting sentiment around the stock’s longer‑term growth story. Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds
• Neutral Sentiment: A sector peer (Intellia) reported strong Q4 results and its shares jumped, reflecting ongoing investor appetite for gene‑editing / biotech winners; this may lift sector flows but is not specific to Regeneron’s fundamentals. Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
• Negative Sentiment: Some coverage notes Regeneron has underperformed the Nasdaq over the past year, which could cap short‑term multiple expansion despite product wins — a cautionary note for momentum traders. Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Insiders Place Their Bets

In related news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the sale, the director directly owned 17,803 shares in the company, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 5,274 shares of company stock valued at $4,142,738. 7.02% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on REGN. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Evercore upped their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday, January 22nd. Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their price target for the company from $627.00 to $860.00 in a research report on Wednesday, January 7th. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Finally, JPMorgan Chase & Co. increased their target price on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $793.81.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.